Further insights into antimicrobial and cytotoxic potential of Achillea millefolium herb methanol and dichloromethane extracts

Industrial Crops and Products, Год журнала: 2025, Номер 225, С. 120553 - 120553

Опубликована: Янв. 23, 2025

Язык: Английский

---

Novel steroidal oximes as antiproliferative agents: Design, synthesis and biological activity evaluation

Bioorganic Chemistry, Год журнала: 2025, Номер 156, С. 108229 - 108229

Опубликована: Янв. 30, 2025

Язык: Английский

---

Directing mineralization of ZnO nanoparticles in cyanobacterial liquid crystalline polysaccharides for cancer therapies

International Journal of Biological Macromolecules, Год журнала: 2025, Номер unknown, С. 140716 - 140716

Опубликована: Фев. 1, 2025

Язык: Английский

---

Magnetic–Plasmonic Core–Shell Nanoparticles: Properties, Synthesis and Applications for Cancer Detection and Treatment

Nanomaterials, Год журнала: 2025, Номер 15(4), С. 264 - 264

Опубликована: Фев. 10, 2025

Nanoparticles have been widely used in cancer diagnostics and treatment research due to their unique properties. Magnetic nanoparticles are popular imaging techniques ability alter the magnetization field around them. Plasmonic mainly applied treatments like photothermal therapy convert light into heat. While these among respective fields, magnetic–plasmonic core–shell (MPNPs) gained popularity recent years combined magnetic optical properties from core shell. MPNPs stood out theranostics as a multimodal platform capable of serving contrast agent for imaging, guidable drug carrier, causing cellular ablation through energy conversion. In this review, we summarize different most common synthesis approaches. We particularly discuss applications diagnosis based on mechanisms using particles. Lastly, look current challenges they face clinical future perspectives detection therapy.

Язык: Английский

---

Mechanisms of Cell Death Induced by Cannabidiol Against Tumor Cells: A Review of Preclinical Studies

Plants, Год журнала: 2025, Номер 14(4), С. 585 - 585

Опубликована: Фев. 14, 2025

Commonly known as marijuana or hemp, Cannabis sativa L. (Cannabaceae), contains numerous active compounds, particularly cannabinoids, which have been extensively studied for their biological activities. Among these, cannabidiol (CBD) stands out its therapeutic potential, especially given non-psychotropic effects. This review evaluates the antitumor properties of CBD, highlighting various mechanisms action, including induction apoptosis, autophagy, and necrosis. By synthesizing findings from in vitro studies on cell death signaling pathways activated by CBD human tumor lines, this literature emphasizes promise natural antineoplastic agent. We conducted a comprehensive search articles PubMed, Scopus, Springer, Medline, Lilacs, Scielo databases 1984 to February 2022. Of forty-three included, majority (68.18%) reported that activates while 18.18% observed simultaneous apoptosis 9.09% focused autophagy alone, 4.54% indicated The effects appear be mediated transient receptor potential cation channels (TRPVs) endometrial cancer, glioma, bladder myeloma, with TRPV1, TRPV2, TRPV4 playing key roles activating apoptosis. knowledge paves way innovative strategies may enhance cancer treatment outcomes minimizing toxicity side associated conventional therapies.

Язык: Английский

---

The Progress of Molybdenum Disulfide 2D Nanosheets as Bionanocarriers for Drug Delivery Systems: A Groundbreaking Approach with Multiple Therapeutic Applications

Journal of Inorganic and Organometallic Polymers and Materials, Год журнала: 2025, Номер unknown

Опубликована: Март 27, 2025

Язык: Английский

---

Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition

Cell Death and Differentiation, Год журнала: 2025, Номер unknown

Опубликована: Апрель 9, 2025

Abstract The stress-associated chaperone system is an actionable target in cancer therapies. It ubiquitously upregulated tissues and enables tumorigenicity by stabilizing oncoproteins. Most inhibitors the key component, heat-shock protein 90 (HSP90). Although HSP90 are highly tumor-selective, they fail clinical trials. These failures partly due to interference with a negative regulatory feedback loop response (HSR): inhibition, there compensatory synthesis of stress-inducible chaperones, mediated transcription factor heat-shock-factor 1 (HSF1). We recently identified that wild-type p53 reduces HSR repressing HSF1 via p21-CDK4/6-MAPK-HSF1 axis. Here, we test whether HSP90-based therapies, simultaneous activation or direct cell cycle inhibition interrupts deleterious HSF1-HSR axis improves efficiency inhibitors. found clinically relevant activator Idasanutlin suppresses activity inhibitor-based This combination synergistically viability accelerates death p53-proficient colorectal (CRC) cells, murine tumor-derived organoids, patient-derived organoids (PDOs). Mechanistically, upon therapy, CRC cells upregulate p53-associated pathways, apoptosis, inflammatory pathways. Likewise, mouse model, dual HSF1-HSP90 represses tumor growth remodels immune composition. Importantly, cyclin-dependent kinases 4/6 (CDK4/6) under phenocopies synergistic repression cells. Moreover, p53-deficient CDK4/6 similarly growth. p53-mutated PDOs respond providing strategy independent status. In sum, provide new options improve therapies enhance

Язык: Английский

---

Potential of Carbon Nanodots (CNDs) in Cancer Treatment

Nanomaterials, Год журнала: 2025, Номер 15(7), С. 560 - 560

Опубликована: Апрель 6, 2025

Carbon Nanodots (CNDs) are characterized by their nanoscale size (<10 nm), biocompatibility, stability, fluorescence, and photoluminescence, making them a promising candidate for cancer therapy. The difference in the methods of synthesis CNDs, whether top-down or bottom-up, affects formation, visual, surface characteristics which crucial biomedical pharmaceutical applications. urgent need innovative therapeutic strategies from CNDs is due to limitations barriers posed conventional therapies including drug resistance cytotoxicity. Nano-loaded chemotherapy treatments highly effective can enhance solubility targeted delivery chemotherapeutic agents, generate reactive oxygen species (ROS) induce cell cytotoxicity, regulate intracellular signaling pathways. Their ability be designed cellular uptake exact localization further improves potential. In addition working on delivery, highlighted dual functionality imaging therapy, allows real-time observing treatment efficacy. Despite development these results future, challenges still exist treatment.

Язык: Английский

---

Harnessing the Power of Natural Terpenoid Compounds Against Esophageal Squamous Cell Carcinoma: A Systematic Review

Future Pharmacology, Год журнала: 2025, Номер 5(2), С. 21 - 21

Опубликована: Май 6, 2025

Background/Objectives: Limitations of conventional treatments for esophageal cancer, which include poor solubility, drug resistance, and undesirable side effects, make it imperative to explore new therapeutic approaches slow the progression this disease. This study aims assess potential terpene compounds as anti-cancer agents squamous cell carcinoma (ESCC). Methods: work was carried out following PRISMA 2020 guidelines ensure rigorous methodology. Results: A systematic analysis 34 revealed various mechanisms action, such induction oxidative stress modulation apoptotic pathways. The results also show that several compounds, including (1Z,3R,4S,5E,7Z)-1-bromo-3,4,8-trichloro-7-(dichloromethyl)-3-methylocta-1,5,7-triene, dehydrocostus lactone, (3R,4S)-3,4,6,7-tetrachloro-3,7-dimethyl-octene-1-ene, acetyl-macrocalin B, jesridonin, longikaurin A, sphaerococcenol DS2, rabdocoestin ingenol C, ingenol-3,20-dibenzonate, JDA-202, xerophilusin betulinic acid, euphol, (20S) ginsenoside Rh2, with IC50s below 10 µM, promising efficacy both in vitro vivo, sometimes surpassing certain treatments. Conclusions: However, despite these encouraging prospects, limitations remain, notably a lack vivo data clearly defined action compounds. These challenges require further research validate their safety efficacy, facilitating development viable options ESCC.

Язык: Английский

---

An evaluation of patritumab deruxtecan for the treatment of EGFR -mutated non-small cell lung cancer

Expert Opinion on Biological Therapy, Год журнала: 2025, Номер unknown

Опубликована: Май 15, 2025

Epidermal growth factor receptor (EGFR) mutations represent targetable alterations in non-small cell lung cancer (NSCLC). The treatment landscape the frontline setting for patients with advanced EGFR-mutated NSCLC is evolving increasing options. EGFR tyrosine kinase inhibitors (TKIs) have significantly improved outcomes, but resistance inevitably develops, necessitating alternative strategies. Patritumab deruxtecan a novel antibody-drug conjugate targeted human epidermal receptor-3 (HER3), delivering topoisomerase-I inhibitor payload to HER3-expressing cells. Phase I and II studies demonstrated efficacy EGFR-mutant disease progression after prior therapies, including third-generation TKIs platinum-based chemotherapy. phase-II trial reported an objective response rate of 39% median progression-free survival 5.5 months. associated notable toxicities, grade 3 higher hematologic adverse events, gastrointestinal toxicity, interstitial (ILD). ILD occurred 5.3% Phase-II study. Early detection management are crucial minimizing risk complications. Patients who received TKI therapy chemotherapy limited demonstrates clinical activity this population manageable side effects, addressing unmet need patients.

Язык: Английский

---